RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM
Bolton Medical, Inc. · Decision date Oct 10, 2025
What did the FDA approve?
FDA records P110038/S033 as a supplement to PMA P110038, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Oct 10, 2025.
FDA approval order statement
approval for labeling updates to include the final study results of the Relay Thoracic Stent-Graft with Plus Delivery System Pivotal, Continued Access, and Post Approval Studies
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 10, 2025
- FDA change category
- Labeling Change - PAS
Regulatory record facts
- Identifier
- P110038/S033
- Regulatory pathway
- PMA supplement
- Applicant
- Bolton Medical, Inc.
- Product code
- MIH
- Decision code
- APPR
- Decision date
- Oct 10, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT.
- Applicant
- Bolton Medical, Inc.
- Product code
- MIH
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P110038/S033 received
Application receipt date recorded by FDA.
P110038/S034 · Related supplement
RelayPlus
P110038/S033 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P110038. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P110038
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
RelayPlusP110038/S034 | Bolton Medical, Inc. | PMA supplement | Sep 3, 2025 | FDA |
Explore the linked device profile
Other records with product code MIH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
RelayPro Thoracic Stent-Graft Delivery SystemP200045/S025 | Bolton Medical, Inc. | PMA supplement | Oct 28, 2026 | FDA |
| Cook, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Cook, Inc. | PMA supplement | Aug 4, 2026 | FDA | |
| Cook Medical Incorporated | PMA supplement | Aug 4, 2026 | FDA | |
| William Cook Europe Aps | PMA supplement | Aug 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bolton Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 799 International Pkwy., Sunrise, FL, 33325
Sources and methodology
- Original FDA record: P110038/S033
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


